Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM ALLEN PEARCE

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1831457555
CMS profile
1013600
Location
BEAUMONT, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,111.51

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $1,390.00 1
Food and Beverage $721.51 24

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM ALLEN PEARCE

NPI 1831457555 · CMS profile ID 1013600

Allopathic & Osteopathic Physicians / Ophthalmology

BEAUMONT, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831457555?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM ALLEN PEARCE, NPI 1831457555, CMS profile ID 1013600. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831457555?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WILLIAM ALLEN PEARCE, NPI 1831457555, CMS profile ID 1013600. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831457555?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WILLIAM ALLEN PEARCE, NPI 1831457555, CMS profile ID 1013600, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1831457555?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $2,111.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.7612/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111991 CMS
ABBVIE INC. $34.7811/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111989 CMS
Regeneron Healthcare Solutions, Inc. $39.2611/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360553 CMS
Astellas Pharma US Inc $31.9911/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034631453 CMS
Alimera Sciences, Inc. $23.4110/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993545131 CMS
Alimera Sciences, Inc. $13.5010/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993545077 CMS
Regeneron Healthcare Solutions, Inc. $35.8310/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360547 CMS
Genentech USA, Inc. $32.2110/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040597943 CMS
Alimera Sciences, Inc. $1,390.0009/27/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012034807 CMS
ABBVIE INC. $33.4409/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111987 CMS
Astellas Pharma US Inc $32.4409/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034492215 CMS
Apellis Pharmaceuticals, Inc. $22.2408/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056331103 CMS
Regeneron Healthcare Solutions, Inc. $38.0108/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360541 CMS
Alimera Sciences, Inc. $24.4308/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993543983 CMS
ABBVIE INC. $28.6208/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111985 CMS
Apellis Pharmaceuticals, Inc. $21.4206/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056336863 CMS
ABBVIE INC. $20.0406/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111983 CMS
Biogen, Inc. $19.9606/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012288273 CMS
Regeneron Pharmaceuticals, Inc. $93.8805/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000029781 CMS
Bausch & Lomb Americas Inc. $22.5205/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1037893877 CMS
ABBVIE INC. $27.8205/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111981 CMS
Regeneron Healthcare Solutions, Inc. $33.8204/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999360535 CMS
Biogen, Inc. $19.4603/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012236737 CMS
Apellis Pharmaceuticals, Inc. $19.0103/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056311103 CMS
ABBVIE INC. $28.6603/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998111979 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $142.71 6
PY2020 $69.31 3
PY2021 $207.93 7
PY2022 $80.27 3
PY2023 $2,111.51 25
PY2024 $565.87 20
PY2025 $678.73 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,008.49 1
PY2025 Principal investigator $669,959.92 272
PY2024 Principal investigator $33,800.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

273 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $5,266.00 12/24/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237676
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,000.00 12/23/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803150
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14.85 12/23/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803152
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $255.00 12/23/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803154
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $67,104.00 12/22/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803148
Principal investigator 1 Ocular Therapeutix, Inc. $270.00 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278458
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278462
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278464
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278466
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278468
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278470
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184278474
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $255.00 12/18/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803572
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 12/17/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708359
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 12/17/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708361
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Retina Consultants of Texas
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $432.00 12/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184275589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/15/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184275591
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $5,115.00 12/11/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803570
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $255.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803146
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $5,907.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803562
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $1,204.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803564
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803566
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $1,524.00 12/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803568
Principal investigator 1 Ocular Therapeutix, Inc. $372.05 12/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237613
Principal investigator 1 Ocular Therapeutix, Inc. $30.80 12/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237625
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,120.85 12/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184266557
Principal investigator 1 Ocular Therapeutix, Inc. $1,313.00 11/21/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237566
Principal investigator 1 Ocular Therapeutix, Inc. $5,650.00 11/21/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237574
Principal investigator 1 Ocular Therapeutix, Inc. $270.00 11/19/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237542
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $19,818.00 11/10/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803560
Principal investigator 1 Ocular Therapeutix, Inc. $3,580.00 11/05/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237506
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $7,553.00 11/04/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184257053
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708329
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 11/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708349
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $510.00 10/30/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803552
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $149.00 10/30/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803554
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $507.00 10/30/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803556
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,323.00 10/30/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184256219
Principal investigator 1 Ocular Therapeutix, Inc. $10,532.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/29/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255159
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 10/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708351
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 10/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708353
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 10/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708355
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 10/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708357
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,060.72 10/20/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803140
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,425.00 10/20/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803142
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,153.95 10/20/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803144
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/16/2025 Non-covered Recipient Entity
Retina Consultants of Texas
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184251105
Principal investigator 1 Ocular Therapeutix, Inc. $3,222.58 10/15/2025 Non-covered Recipient Entity
Retina Consultants of Texas
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237961
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,099.65 10/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803128
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,099.65 10/13/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249751
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $6,344.00 10/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803550
Principal investigator 1 Ocular Therapeutix, Inc. $3,469.22 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237418
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184248060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184248062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/08/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184248064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 10/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184246171
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708327
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14.85 10/01/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803138
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 09/24/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708319
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 09/24/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708321
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 09/24/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708323
Principal investigator 1 Boehringer Ingelheim International GmbH $102.08 09/24/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708325
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708347
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.10 09/22/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/22/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238830
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $471.25 09/17/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184238862
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,436.00 09/15/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803126
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $6,656.00 09/15/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803544
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,843.15 09/12/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803134
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,234.65 09/12/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184236313
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $255.00 09/10/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803546
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $12,266.00 09/10/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803548
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $170.00 09/04/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803124
Principal investigator 1 Ocular Therapeutix, Inc. $3,672.22 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237241
Principal investigator 1 Ocular Therapeutix, Inc. $203.00 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237257
Principal investigator 1 Ocular Therapeutix, Inc. $5,266.00 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237268
Principal investigator 1 Ocular Therapeutix, Inc. $23,311.00 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237272
Principal investigator 1 Ocular Therapeutix, Inc. $406.00 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237346
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234507
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,695.60 09/03/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234515
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184232682
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 08/26/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708307
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 08/26/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708309
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 08/26/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708311
Principal investigator 1 Boehringer Ingelheim International GmbH $83.52 08/26/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708313
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 08/26/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708315
Principal investigator 1 Boehringer Ingelheim International GmbH $3.05 08/26/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708317
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $555.00 08/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227187
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 08/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184227213
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,893.40 08/08/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224278
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708303
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 08/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708341
Principal investigator 1 Ocular Therapeutix, Inc. $203.00 08/01/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,205.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222280
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222292
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 07/28/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708343
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 07/28/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708345
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $406.00 07/28/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803540
Principal investigator 1 Ocular Therapeutix, Inc. $14,528.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237144
Principal investigator 1 Ocular Therapeutix, Inc. $15,719.00 07/25/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237148
Principal investigator 1 Ocular Therapeutix, Inc. $1,486.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $77.00 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.99 07/10/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213674
Principal investigator 2 Boehringer Ingelheim Pharmaceuticals, Inc. $494.00 07/09/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220803538
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 07/09/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237079
Principal investigator 1 Ocular Therapeutix, Inc. $3,469.22 07/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237061
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708301
Recipient Ocular Therapeutix, Inc. $11,008.49 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229416
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,300.00 06/24/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 No dispute reported 06/30/2026 1220803518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $149.96 06/19/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220806213
Principal investigator 1 Ocular Therapeutix, Inc. $540.00 06/18/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237005
Principal investigator 1 Ocular Therapeutix, Inc. $2,520.80 06/13/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236996
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 06/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184204035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/04/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184204037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202139
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202143
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202491
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 06/02/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202901
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708299
Principal investigator 1 Ocular Therapeutix, Inc. $4,964.64 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236947
Principal investigator 1 Ocular Therapeutix, Inc. $2,754.00 05/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236949
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 05/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708333
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 05/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708335
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 05/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708337
Principal investigator 1 Boehringer Ingelheim International GmbH $7.00 05/27/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 No dispute reported 06/30/2026 1220708339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 05/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 05/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $290.25 05/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198603
Principal investigator 1 Ocular Therapeutix, Inc. $33.00 05/21/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236917
Principal investigator 1 Ocular Therapeutix, Inc. $7,020.00 05/16/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236904
Principal investigator 1 Ocular Therapeutix, Inc. $26,653.00 05/14/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236892
Principal investigator 1 Ocular Therapeutix, Inc. $2,520.80 05/09/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236854
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184187881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,750.00 04/21/2025 Non-covered Recipient Entity
Rctx-Texas Medical Center Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220803120
Principal investigator 1 Ocular Therapeutix, Inc. $1,063.00 04/11/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250236810
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $239.30 04/03/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220806211
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708295
Principal investigator 1 Ocular Therapeutix, Inc. $3,517.30 03/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237042
Principal investigator 1 Ocular Therapeutix, Inc. $33.00 03/28/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/26/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184179546
Principal investigator 1 Boehringer Ingelheim International GmbH $7.44 03/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708293
Principal investigator 1 Ocular Therapeutix, Inc. $15,502.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF HOUSTON PLLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250237015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,838.00 03/12/2025 Non-covered Recipient Entity
RETINA CONSULTANTS OF TEXAS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172284
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708279
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 02/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708281
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708283
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708285
Principal investigator 1 Boehringer Ingelheim International GmbH $85.84 02/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708287
Principal investigator 1 Boehringer Ingelheim International GmbH $9.00 02/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708289
Principal investigator 1 Boehringer Ingelheim International GmbH $1.83 02/25/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708291
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708277
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708269
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 01/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708271
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 01/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708273
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 01/01/2025 Non-covered Recipient Entity
Retina Consultants Of Texas Beaumont Retina Center
A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. No dispute reported 06/30/2026 1220708275